FOCUS AREAS

The Netherlands Cancer Institute has a comprehensive end-to-end experience, ranging from basic research to pre-clinical and clinical studies. At the Early Drug Development Center (EDDC), we focus on Industry-sponsored early clinical research, Investigator Initiated Studies (IIS) and translational work. Our focus areas are divided into industry-sponsored phase 1 clinical trials; precision medicine (precision dosing and precision drug formulation); genomic profile selected phase 1 and 2 studies and repurposing. We have more than 20 years of high-level expertise in development of complex phase 1, first-in-human, and phase 2 studies. These studies are performed for an extensive wide range of solid cancer tumors. We aim to achieve a more promising and personalized medicine for our patients, with the development of targeted therapy, immunotherapy, cell therapies and therapeutic drug monitoring of anti-cancer drugs.

The unique position of the EDDC

The EDDC has high-quality standards, according to the applicable Dutch, European & FDA guidelines and regulations. We also have an in-house pharmacy, with GLP, GMP and GDP licenses, which is unique in Europe. This privileged situation enables us to perform drug formulation and distribution. In addition, thorough pharmacological research, such as mass balance studies, measurement of intracellular metabolites, pharmacokinetics, or pharmacodynamics modeling, is carried out. We also collaborate with different research groups of the NKI. You can find more information about these groups on this page.

We team up with CROs, pharmaceutical companies and other important stakeholders (global and local medical networks) in early clinical research. We do this in order to have the highest possible impact on the life of cancer patients. We have a standard way of working and clear agreements with the pharmaceutical industry. This forms the base for good and constructive collaborations. You can find a list of our partners here. Moreover, based in Amsterdam, the Netherlands, we have a strategic location in the EU, with excellent infrastructure and international connections, fully equipped for phase 1 and 2 studies, easy access to patients and EMA proximity. Thanks to this favorable situation, the EDDC alone is able to see around 300 patients per year.

You can find more information about the EDDC and our research here.